Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Study to Predict Optimized Treatment in ADHD (iSPOT-A)
2009-013272-47Phase 4Terminated
- Sponsor
- Biopharmaceutical Research Company
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Biopharmaceutical Research Company. Primary endpoints: Objective markers for ADHD diagnosis and treatment evaluation, Marker normalization with treatment and 1 more. Started Nov 2011; status: terminated.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2009-013272-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013272-47.